EP0771562A2 — Improved preparation for colonic evacuation
Assigned to RED HILL BIOPHARMA Ltd · Expires 1997-05-07 · 29y expired
What this patent protects
The present invention relates to an osmotic colonic evacuant in solid oral dosage form comprising an orthostatic lavage in powder form and a pharmaceutically acceptable excipient, diluent and/or adjuvant. The present invention also relates to an osmotic colonic evacuant in …
USPTO Abstract
The present invention relates to an osmotic colonic evacuant in solid oral dosage form comprising an orthostatic lavage in powder form and a pharmaceutically acceptable excipient, diluent and/or adjuvant. The present invention also relates to an osmotic colonic evacuant in powder form together with a diluent for use in a method of evacuating a patient's colon, a method of treating a small bowel bacterial overgrowth or irritable bowel syndrome, or a method of treating acute of chronic bacterial bowel infection. The present invention further relates to two or more osmotic colonic evacuants for use in sequential oral administration to a patient in two or more treatment regimens, wherein the first evacuant is in solid oral unit dosage form adapted and presented for a first administration period and the second evacuant is in solid oral unit dosage form adapted and presented for a second administration period.
Drugs covered by this patent
- Renacidin (CITRIC ACID) · Baxter
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.